Elesclomol (also known by the developmental code name STA-4783) is a synthetic small‑molecule anticancer agent whose proposed mechanism of action involves the induction of oxidative stress in tumor cells. The drug forms a complex with copper ions; the resulting complex is thought to generate reactive oxygen species (ROS) that disrupt mitochondrial function and trigger apoptosis in cancer cells.
Chemical and Pharmacological Characteristics
- Chemical class: Phenoxazine derivative.
- Molecular formula: C₁₇H₁₆ClN₃O₂S.
- Molecular weight: Approximately 374.84 g·mol⁻¹.
- Administration: Investigated primarily as an intravenous infusion.
Mechanism of Action
- Copper‑dependent ROS generation: Elesclomol chelates copper (II) ions, forming a redox‑active complex that catalyzes the production of superoxide and hydrogen peroxide within mitochondria.
- Mitochondrial dysfunction: The elevated ROS levels cause loss of mitochondrial membrane potential, leading to activation of intrinsic apoptotic pathways.
- Selective cytotoxicity: Pre‑clinical studies suggested that cells with higher baseline oxidative stress or defective antioxidant defenses were more susceptible to elesclomol‑induced death.
Development History
- Discovery and early research: Identified by the St. Louis–based company Sta. Luca Pharmaceuticals (later Terra Nova Pharmaceuticals) in the early 2000s.
- Pre‑clinical studies: Demonstrated activity against a range of solid tumor cell lines and xenograft models, including melanoma, neuroblastoma, and non‑small‑cell lung carcinoma.
- Phase I/II trials: Conducted in the United States and Europe from 2005 to 2012, establishing dose‑limiting toxicities (primarily neutropenia, fatigue, and hepatic enzyme elevations) and a recommended phase II dose.
Clinical Evaluation
- Phase III trial (S-Phase I): A randomized, double‑blind, placebo‑controlled study of elesclomol combined with paclitaxel in patients with advanced melanoma (NCT00594941). The trial met its primary endpoint of progression‑free survival (PFS) in the subgroup of patients with low lactate dehydrogenase (LDH) levels but failed to demonstrate a statistically significant overall survival benefit across the entire population.
- Regulatory status: The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have not granted marketing authorization for elesclomol. Development has been discontinued for melanoma, though exploratory investigations in other tumor types (e.g., ovarian cancer, multiple myeloma) have been reported in the literature.
- Current research: Small‑scale studies continue to examine the drug’s activity in combination with agents that affect cellular redox balance, such as bortezomib or glutathione synthesis inhibitors. No ongoing large‑scale pivotal trials are listed in major clinical trial registries as of 2024.
Safety Profile
- Common adverse events: Fatigue, nausea, neutropenia, thrombocytopenia, hepatic transaminase elevations.
- Serious toxicities: Rare cases of severe neutropenic infection and reversible cardiomyopathy have been reported.
- Dose modifications: Clinical protocols typically required dose reductions or treatment interruptions for grade 3 or higher laboratory abnormalities or symptomatic toxicities.
Commercial and Patent Information
- Patents: Multiple patents covering the composition of matter, manufacturing processes, and therapeutic use of elesclomol were filed between 2003 and 2015. Many have expired or are set to expire in the early 2020s.
- Licensing: Intellectual property was transferred to various partners, including Teva Pharmaceutical Industries and Genentech, for co‑development in specific indications. No product approvals have resulted from these agreements.
Summary
Elesclomol is a copper‑binding anticancer compound that exerts cytotoxic effects through ROS‑mediated mitochondrial disruption. While early clinical trials showed promise—particularly in melanoma patients with low LDH—subsequent phase III data did not achieve regulatory approval, and development for most indications has been halted. Ongoing research focuses on understanding the drug’s redox biology and identifying potential synergistic combinations, but no large‑scale clinical programs are currently active.
